The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease

The Effect of Roxadustat on Transfusion-Dependent Myelodysplastic Syndrome Complicated by Chronic Kidney Disease

Haematopoietic insufficiency is the treatment target of lower-risk myelodysplastic syndrome (MDS). Although erythropoiesis-stimulating agents (ESAs) are generally effective for treating anaemia, resistance can develop. Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) improves renal anaemia by pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ryujiro Hara, Naoki Goto, Daisuke Furuya, Toshihiko Kitahara, Hiroki Numata, Shigeki Watanabe, Hiroshi Kawada, Kiyoshi Ando
Formato: article
Lenguaje:EN
Publicado: Karger Publishers 2021
Materias:
myelodysplastic syndrome
hypoxia-inducible factor-prolyl hydroxylase inhibitor
roxadustat
renal anaemia
essential thrombocythemia
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/c6b12a789d3d40dba5e269a5ed0a3177
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c6b12a789d3d40dba5e269a5ed0a3177

Ejemplares similares